For decades, regenerative medicine has relied on a limited and unpredictable source: donated human cadaver tissue. It’s hard to scale, expensive to store, and often unavailable when patients need it most.

 

At XenoTherapeutics, we’re taking a different approach.

 

By using genetically engineered pigs as a consistent, living donor source, we aim to make regenerative therapies more accessible, more reliable, and more responsive to patients’ needs.

 

Our first therapy—realSKIN—is a living skin transplant designed to support healing after severe injury. But realSKIN is just the beginning. We believe this same breakthrough approach can one day replace cadaver tissue across a range of applications.

 

We’re not just building a new product.

We’re building a new model for regenerative medicine.